Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 3;9(6):661–673. doi: 10.1002/sctm.19-0220

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

The platelet and red blood cell (RBC) transfusion for patients receiving haploidentical hematopoietic stem cell transplantation (HSCT) with or without single doses of recombinant human thrombopoietin (TPO) treatment. A, The number of platelet units transfused before platelet engraftment for patients with severe aplastic anemia (SAA) receiving haploidentical HSCT with or without TPO administration. B, The number of platelet units transfused before platelet engraftment for patients with hematologic malignancies receiving haploidentical HSCT with or without TPO treatment. C, The number of RBC units transfused within 60 days after transplantation in patients with SAA. D, The number of RBC units transfused within 60 days after transplantation in patients with hematologic malignancies. *P < .05, **P < .01